Navigation Links
Cellular Dynamics Licenses Technology From ViaCyte
Date:4/13/2011

MADISON, Wis., April 13, 2011 /PRNewswire/ -- Cellular Dynamics International (CDI), the world's largest producer of tissue cells derived from human induced pluripotent stem cell (iPSC) lines, today announced it has strengthened its intellectual property (IP) portfolio by licensing patented definitive endoderm differentiation technology from ViaCyte, Inc., a stem cell company focused on diabetes therapy. CDI will apply this patented methodology in the development and production of iCell® Hepatocytes, iPSC-derived liver cells.  

ViaCyte's proprietary technology covers cell cultures containing specific amounts of definitive endoderm.  Definitive endoderm gives rise to organs and tissues such as the liver, pancreas, lung, intestine, thymus and thyroid. Separately, CDI has agreed to supply iPSC lines to ViaCyte.

Nick Seay, Chief Technology Officer of CDI, acknowledged the importance of this technology to CDI's IP portfolio. "ViaCyte has developed and filed patents on useful methodologies for differentiating into definitive endoderm, which is the normal intermediate in the subsequent manufacturing of hepatocytes. The right to incorporate this technology into our industrial pipeline assures our pharmaceutical customers that they will receive hepatocytes in the quantity, quality and purity that they require. In addition, this brings us a step closer toward developing hepatocyte line extensions, including panels with multiple iPSC starting materials. This step enables our customers to compare responses of tissue cells based on genetic diversity."

"We are pleased to strike this license agreement with CDI," said  John West, Chief Executive Officer of ViaCyte. "Our proprietary technology will facilitate the production of their iPSC-derived hepatocytes. We also look forward to using CDI's human iPSC-derived cells in the generation of pancreatic beta cells, the cells that make insulin, as our research efforts continue in our work on developing stem cell therapies for diabetes treatment."

"This licensing agreement is an important achievement for CDI as we move towards expanding our product line to include hepatocytes," added Chris Parker, Chief Commercial Officer of CDI. "The availability of these liver cells will provide pharmaceutical companies with a reliable source of well-characterized, highly reproducible and readily available human hepatocytes for preclinical drug discovery, hepatotoxicity testing, and disease research."

Terms of the licensing agreement were not disclosed.

About ViaCyte, Inc.

ViaCyte is a preclinical therapeutic company focused on diabetes. Our therapy is based on pancreatic beta cell progenitors (Pro-Islet™) derived from human pluripotent stem cells. These cells are implanted using a durable and retrievable encapsulation device. Once implanted and matured, these cells secrete insulin in response to blood glucose levels. The Company's goal is long term insulin independence without immune suppression, and without hypoglycemia and other diabetes-related complications.

ViaCyte is a private company headquartered in San Diego, California, with additional operations in Athens, Georgia. The Company is funded in part through the support of the California Institute for Regenerative Medicine.

This news release may contain forward-looking statements made pursuant to the "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995.  

About Cellular Dynamics International, Inc.

Cellular Dynamics International, Inc. (CDI) is a leading developer of next-generation stem cell technologies for drug development and personalized medicine applications. CDI harnesses the power of pluripotent stem cells and their ability to differentiate into any cell type for world-class drug development tools. In addition, it is the leader in iPSC technology, the production of pluripotent stem cell-derived lines from adult tissue. CDI was founded in 2004 by Dr. James Thomson, a pioneer in human pluripotent stem cell research at the University of Wisconsin-Madison. CDI's facilities are located in Madison, Wisconsin. See www.cellulardynamics.com.


'/>"/>
SOURCE Cellular Dynamics International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Cellular Dynamics International Scientists Report on Efficient Method to Produce Footprint-Free Induced Pluripotent Stem Cells (iPSCs) Under Feeder-Free Conditions
2. Summer Street Research Partners Closes Financing for ImmunoCellular Therapeutics, Ltd.
3. Cellular Dynamics International to Present at 29th Annual JPMorgan Healthcare Conference
4. Intra-Cellular Therapies Announces Positive Results with ITI-002 in Pre-Clinical Models of Parkinsons Disease
5. International Society for Cellular Therapy (ISCT) joins forces with Roche and Genzyme to launch Cell Therapy Industry Partnership.
6. Aegera Therapeutics Reports Survival Data from the Phase 1 Portion of its Phase 1-2 Study of AEG35156 in Combination with Sorafenib in Patients with Advanced Hepatocellular Carcinoma
7. Human Embryonic-Like Extracellular Matrix Significantly Inhibits Tumor Growth and Cancer Cell Proliferation
8. Promega and Cellular Dynamics Partner to Validate Stem Cell-Based In Vitro Assays for Predicting Drug-Induced Cardiotoxicity
9. Tengion Presents New Data Supporting Key Urologic and Kidney Programs at 16th Annual Meeting of the International Society for Cellular Therapy
10. t2cure First Company to Have Quality of Cellular Therapeutic Certified by EMA
11. iPierian Awarded Basic Biology Grant by California Institute of Regenerative Medicine to Study Cellular Reprogramming
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/20/2017)... , ... July 20, 2017 , ... Corporate Directors Forum ... its 27th annual Director of the Year Awards. , The awards will be presented ... This annual event celebrates directors who have made significantly positive contributions in the ...
(Date:7/18/2017)... ... July 18, 2017 , ... Genedata, a leading ... science and technology company, has implemented Genedata Biologics ™ to scale-up their ... Oncology, Immunology, and Neurodegenerative Diseases. , The need to systematically evaluate large panels ...
(Date:7/18/2017)... ... July 18, 2017 , ... Recently recognized by ... ) announces the migration of its flagship cloud-based product Planet Life Cycle – ... enterprise work management system that merges strategic and financial planning with execution. The ...
(Date:7/17/2017)... ... July 17, 2017 , ... OHAUS ... announced the launch of its new line of Heavy-Duty Orbital Shakers today. , ... analog and digital) for laboratory applications. These shakers are ideal for load ...
Breaking Biology Technology:
(Date:4/5/2017)... 2017 KEY FINDINGS The global ... a CAGR of 25.76% during the forecast period of ... factor for the growth of the stem cell market. ... MARKET INSIGHTS The global stem cell market is ... geography. The stem cell market of the product is ...
(Date:3/30/2017)... March 30, 2017  On April 6-7, 2017, Sequencing.com ... Genome hackathon at Microsoft,s headquarters in ... will focus on developing health and wellness apps that ... Hack the Genome is the first hackathon for ... world,s largest companies in the genomics, tech and health ...
(Date:3/29/2017)... 2017  higi, the health IT company that operates ... America , today announced a Series B investment ... EveryMove. The new investment and acquisition accelerates higi,s strategy ... transform population health activities through the collection and workflow ... higi collects and secures data today on behalf of ...
Breaking Biology News(10 mins):